Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
MP

WKN: A3C7A5 | ISIN: FR0012634822 | Ticker: 4RD
Stuttgart
18.11.26 | 21:55
0,871 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MAAT PHARMA SA Chart 1 Jahr
5-Tage-Chart
MAAT PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,8650,94018.11.

Aktuelle News zur MAAT PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MAAT PHARMA Aktie jetzt für 0€ handeln
MoMaaT Pharma Reports Financial Results for the Third Quarter 2026398Revenues of EUR 0.5 million in the third quarter of 2026 and EUR 1.6 million year-to-date, derived from the Early Access Program As of September 30, 2026, cash and cash equivalents were...
► Artikel lesen
06.11.MaaT Pharma Provides an Update on Preliminary Findings from the Investigator-Sponsored Phase 2a PICASSO Trial in Metastatic Melanoma376PICASSO, an investigator-sponsored study conducted by AP-HP in collaboration with INRAe and Gustave Roussy, evaluated the safety of adding MaaT013 (Xervyteg) to ipilimumab and nivolumab in patients...
► Artikel lesen
19.10.MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors456Positive pre-Investigational New Drug (pre-IND) interaction with the Food Drug Administration (FDA) on Chemistry, Manufacturing and Controls (CMC) and nonclinical topics supports MaaT034's continued...
► Artikel lesen
07.10.Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review356Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH 07.10.2026 / 14:10 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
29.09.MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update632MaaT013 (Xervyteg): In September 2026, following the re-examination procedure, the CHMP maintained its negative opinion on the Conditional Marketing Authorization Application (MAA) for...
► Artikel lesen
21.09.MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors543Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA), focused on CMC (Chemistry, Manufacturing, and Controls), is scheduled for October 2026, representing...
► Artikel lesen
18.09.MaaT Pharma Provides Update on MaaT013 (Xervyteg) Potential Development Plan Following CHMP Negative Opinion After Re-examination681The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the Company's application for a Conditional Marketing Authorization...
► Artikel lesen
15.09.MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg) Following Re-Examination for its Conditional Marketing Authorization Application in Europe548MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)'s Oral Explanation meeting which took place on September 14, 2026 Formal CHMP...
► Artikel lesen
06.07.MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract439Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
02.07.MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital516Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers) Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage...
► Artikel lesen
30.06.Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review423Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH 30.06.2026 / 13:08 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
26.06.EMA committee issues negative opinion on MaaT Pharma's MaaT0135
26.06.MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease1.203The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013...
► Artikel lesen
11.06.Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review370Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH 11.06.2026 / 13:07 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
26.05.MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 20261.048MaaT013 (Xervyteg): In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use...
► Artikel lesen
20.05.MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease1.047During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a "negative trend" opinion for the upcoming June...
► Artikel lesen
11.05.MaaT Pharma to Hold Annual General Meeting on June 16, 2026489Regulatory News: MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing...
► Artikel lesen
21.04.Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy423Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH 21.04.2026 / 15:09 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
01.04.MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal622CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy Results...
► Artikel lesen
31.03.MaaT Pharma Announces 2025 Annual Results and Provides Business Updates782Potential Pivotal Year for MaaT013 (Xervyteg): Marketing Authorization Application (MAA) in Europe for MaaT013 (Xervyteg) submitted to the European Medicines Agency (EMA) in June 2025 ...
► Artikel lesen
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1